Immunohistochemistry PD-L1 SP263 Ventana Test
Understanding PD-L1 Biomarker Testing for Cancer Immunotherapy
The Immunohistochemistry PD-L1 SP263 Ventana Test represents a groundbreaking advancement in precision oncology, providing critical insights into a patient’s potential response to immunotherapy treatments. This sophisticated diagnostic procedure specifically detects the presence and expression levels of programmed death-ligand 1 (PD-L1) proteins on cancer cells, serving as a vital biomarker for immune checkpoint inhibitor therapy selection.
What Does This Test Measure?
This specialized immunohistochemistry test precisely measures PD-L1 protein expression using the highly specific SP263 antibody clone on advanced Ventana automated staining platforms. The test evaluates:
- PD-L1 expression levels on tumor cells
- PD-L1 expression on immune cells within the tumor microenvironment
- Tumor Proportion Score (TPS) for quantitative assessment
- Combined Positive Score (CPS) for comprehensive evaluation
Who Should Consider PD-L1 SP263 Testing?
This test is particularly recommended for patients diagnosed with:
- Non-Small Cell Lung Cancer (NSCLC) – For pembrolizumab and other immunotherapy decisions
- Head and Neck Squamous Cell Carcinoma – Guiding treatment with immune checkpoint inhibitors
- Urothelial Carcinoma – Determining eligibility for advanced bladder cancer therapies
- Melanoma Patients – Assessing PD-L1 status for combination therapy considerations
- Other Solid Tumors – Where immunotherapy may be a treatment option
Clinical Indications and Symptoms
Patients experiencing persistent symptoms or those recently diagnosed with cancer should discuss PD-L1 testing with their oncologist. Early biomarker assessment can significantly impact treatment planning and outcomes.
Key Benefits of PD-L1 SP263 Ventana Testing
- Personalized Treatment Planning – Identifies patients most likely to benefit from immunotherapy
- Improved Response Rates – Helps avoid ineffective treatments and associated side effects
- Cost-Effective Care – Prevents unnecessary spending on treatments unlikely to work
- Enhanced Survival Outcomes – Enables selection of optimal first-line therapies
- Comprehensive Biomarker Assessment – Provides detailed PD-L1 expression data for clinical decision-making
Understanding Your Test Results
Interpretation Guidelines
Your PD-L1 SP263 test results will include detailed information about PD-L1 expression levels:
- Positive Result – Indicates significant PD-L1 expression, suggesting potential responsiveness to immunotherapy
- Negative Result – Shows minimal PD-L1 expression, which may indicate alternative treatment approaches
- Quantitative Scores – TPS or CPS values that help determine specific treatment thresholds
- Pattern Analysis – Evaluation of staining patterns on tumor cells versus immune cells
Your oncologist will interpret these results in the context of your specific cancer type, stage, and overall health status to develop the most effective treatment plan.
Test Pricing and Availability
| Test Name | Discount Price | Regular Price |
|---|---|---|
| Immunohistochemistry PD-L1 SP263 Ventana Test | $176 USD | $300 USD |
Turnaround Time and Sample Requirements
- Sample Submission: Daily by 6 PM
- Report Timeline: Block samples – 5 days | Tissue Biopsy – 5 days | Complex tissue – 7 days
- Sample Type: Tumor tissue in 10% formal-saline OR formalin-fixed paraffin-embedded block
- Shipping: Room temperature
- Required Documentation: Histopathology report, biopsy site information, and clinical history
Nationwide Accessibility
GGC DNA maintains comprehensive testing facilities across the United States, with branches in all major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, and San Jose. Our nationwide network ensures timely sample processing and rapid result delivery regardless of your location.
Book Your PD-L1 SP263 Test Today
Take the next step in your cancer treatment journey with precise biomarker testing. Our expert team of pathologists and oncology specialists are ready to provide you with the critical information needed for informed treatment decisions.
Call or WhatsApp us today at +1(267) 388-9828 to schedule your PD-L1 SP263 Ventana test and unlock personalized cancer care options.
Early biomarker assessment can make a significant difference in your treatment outcomes. Don’t delay – contact us now to discuss your testing needs and take control of your cancer care journey with advanced precision medicine from GGC DNA.
